Special Drug Use-results Survey for Long-term Use (Fostamatinib)

Sponsor
Kissei Pharmaceutical Co., Ltd.
Study ID
NCT06757257
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Idiopathic Thrombocytopenic Purpura

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.

Key Dates

Start date
May 29, 2023
Status verified
Dec 2024
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
149 participants (estimated)

Arms

  • Arm: fostamatinib treatmented

Primary Outcome Measure

Adverse events [ Time Frame: 18 months ]

Central Contacts